Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Charlotte Charpentier and Diane Descamps.
Connection Strength

5.027
  1. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018 04 01; 73(4):1039-1044.
    View in: PubMed
    Score: 0.761
  2. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses. 2018 01 18; 10(1).
    View in: PubMed
    Score: 0.751
  3. Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. Diagn Microbiol Infect Dis. 2021 Oct; 101(2):115430.
    View in: PubMed
    Score: 0.236
  4. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis. 2021 Oct; 40(10):2235-2241.
    View in: PubMed
    Score: 0.234
  5. Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements. J Virol Methods. 2021 05; 291:114086.
    View in: PubMed
    Score: 0.232
  6. Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott). J Clin Virol. 2020 11; 132:104618.
    View in: PubMed
    Score: 0.225
  7. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
    View in: PubMed
    Score: 0.206
  8. HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man. Open Forum Infect Dis. 2018 Oct; 5(10):ofy223.
    View in: PubMed
    Score: 0.196
  9. Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. J Infect Dis. 2018 08 24; 218(7):1027-1036.
    View in: PubMed
    Score: 0.196
  10. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS One. 2018; 13(6):e0198334.
    View in: PubMed
    Score: 0.193
  11. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671.
    View in: PubMed
    Score: 0.193
  12. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
    View in: PubMed
    Score: 0.187
  13. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017 10 01; 72(10):2954-2955.
    View in: PubMed
    Score: 0.184
  14. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 10; 83(4):e1-e3.
    View in: PubMed
    Score: 0.060
  15. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
    View in: PubMed
    Score: 0.060
  16. Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct; 27(10):1520.e1-1520.e5.
    View in: PubMed
    Score: 0.059
  17. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 Jul; 83(1):119-145.
    View in: PubMed
    Score: 0.059
  18. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. J Infect. 2021 05; 82(5):186-230.
    View in: PubMed
    Score: 0.058
  19. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect. 2020 12 08.
    View in: PubMed
    Score: 0.057
  20. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. J Am Acad Dermatol. 2020 Oct; 83(4):1219-1222.
    View in: PubMed
    Score: 0.056
  21. Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. Clin Infect Dis. 2019 08 30; 69(6):1019-1026.
    View in: PubMed
    Score: 0.052
  22. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
    View in: PubMed
    Score: 0.052
  23. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019 05 01; 74(5):1417-1424.
    View in: PubMed
    Score: 0.051
  24. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375.
    View in: PubMed
    Score: 0.051
  25. New insights are game-changers in HIV-2 disease management. Lancet HIV. 2019 04; 6(4):e214.
    View in: PubMed
    Score: 0.051
  26. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
    View in: PubMed
    Score: 0.050
  27. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother. 2018 10 01; 73(10):2716-2720.
    View in: PubMed
    Score: 0.049
  28. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018 09 28; 67(8):1161-1167.
    View in: PubMed
    Score: 0.049
  29. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clin Infect Dis. 2018 05 17; 66(11):1785-1793.
    View in: PubMed
    Score: 0.048
  30. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
    View in: PubMed
    Score: 0.048
  31. Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients. J Antimicrob Chemother. 2018 05 01; 73(5):1173-1176.
    View in: PubMed
    Score: 0.048
  32. Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. J Virol Methods. 2018 07; 257:12-15.
    View in: PubMed
    Score: 0.048
  33. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. J Clin Virol. 2017 11; 96:49-53.
    View in: PubMed
    Score: 0.046
  34. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12(7):e0180888.
    View in: PubMed
    Score: 0.045
  35. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
    View in: PubMed
    Score: 0.045
  36. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146.
    View in: PubMed
    Score: 0.044
  37. Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study. PLoS One. 2017; 12(2):e0172809.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.